Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools ACC

ACC

Programs, trials, and reported response and survival for adenoid cystic carcinoma.

Data as of 11.07.2026

ACC pipeline

Studies

Trials grouped by drug. Open a study for its arms and the response, survival, and safety figures a source reports.

29 studies across 23 of 23 drugs. 29 studies are in the file.

Amivantamab1 study

Anlotinib + Epirubicin (neoadjuvant)1 study

Apatinib1 study

APG-115 (alrizomadlin)1 study

  • NCT03781986NCT03781986Phase 1/2Active, not recruitingn 41

Axitinib (off Label)2 studies

CB-1032 studies

Emiltatug Ledadotin (Emi-Le, XMT-1660)1 study

Enfortumab Vedotin1 study

HG1461 study

  • HG146NCT06781567Phase 2Recruitingn 140

Ivonescimab1 study

  • I-MACNCT06805617Phase 2Recruitingn 35

Lenvatinib (off Label)3 studies

LUTETIUM-177 PSMA Radioligand2 studies

NN32011 study

Osugacestat (AL101, BMS-906024)1 study

Puxitatug Samrotecan (P-Sam, AZD8205)1 study

Regorafenib (off Label)1 study

REM-4221 study

  • ARIANCT06118086Phase 1/2Recruitingn 125

RGT-611592 studies

Rivoceranib1 study

Sacituzumab Tirumotecan (sac-TMT)1 study

  • STRAPNCT07521670Phase 2Not yet recruitingn 68

SX-682 + Docetaxel1 study

VMD-9281 study

Zanzalintinib1 study

  • ZANACCNCT07682675Phase 2Not yet recruitingn 51